Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Emotional words evoke region- and valence-specific patterns of concurrent neuromodulator release in human thalamus and cortex.

Cell reports·2026

Same author

Dopamine dynamics in human anterior cingulate cortex during Pavlovian-instrumental conflict.

bioRxiv : the preprint server for biology·2026

Same author

Outcomes according to timely or delayed primary percutaneous coronary intervention or fibrinolysis in a national registry of patients with ST-segment elevation myocardial infarction.

Open heart·2026

Same author

S1PR3 mediates glial stimulated tumor invasion in response to interstitial fluid flow.

bioRxiv : the preprint server for biology·2026

Same author

Scrotal hernias in dogs should not be ruled out based on castration status and may require enterectomy.

Journal of the American Veterinary Medical Association·2025

Same author

Persistent Tic Disorders Are Associated With 17q12 Duplications.

Research square·2025

Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026

Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026

Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026

Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026

Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026

Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 26, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Clinical Theranostics in Recurrent Gliomas: A Review.

Austin R Hoggarth^1,2,3, Sankar Muthukumar², Steven M Thomas²

¹Department of Neurosurgery, Carilion Clinic, 1906 Belleview Avenue, Roanoke, VA 24014, USA.

|May 11, 2024

Summary

This summary is machine-generated.

Theranostics, combining diagnostic and therapeutic roles, show promise for recurrent gliomas. This approach improves diagnosis and treatment, potentially enhancing quality of life for brain tumor patients.

Keywords:

GBM QOL functional quality of life glioblastoma theranostics

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jun 26, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

Area of Science:

Neuro-oncology
Nuclear Medicine
Radiology

Background:

Gliomas are the most common malignant brain tumors, with high-grade types having a poor prognosis.
Recurrent high-grade gliomas are challenging to diagnose using standard MRI, which cannot differentiate tumor progression from treatment effects.
Current diagnostic methods lack direct therapeutic capabilities.

Purpose of the Study:

To review the evolving role of theranostics in diagnosing and treating recurrent gliomas.
To explore the impact of theranostics on patient quality of life and functional recovery.

Main Methods:

Review of recent advances in positron emission tomography (PET) and theranostic applications.
Analysis of PET tracers in delineating tumor margins and guiding treatment for recurrent gliomas.
Discussion of the dual diagnostic and therapeutic capabilities of theranostic agents.

Main Results:

PET imaging demonstrates success in defining tumor boundaries and informing treatment strategies for recurrent gliomas.
Theranostics offer a combined diagnostic and therapeutic approach, moving beyond purely diagnostic roles.
The integration of theranostics presents a significant advancement in managing recurrent gliomas.

Conclusions:

Theranostics are increasingly vital in the diagnosis and treatment of recurrent gliomas.
This approach holds potential for improving patient outcomes, quality of life, and functional recovery.
Further research into theranostic applications is warranted for advanced brain tumor management.